KR100531969B1 - 치환된 3-시아노 퀴놀린, 이를 함유하는 약제학적 조성물 및 이의 제조방법 - Google Patents

치환된 3-시아노 퀴놀린, 이를 함유하는 약제학적 조성물 및 이의 제조방법 Download PDF

Info

Publication number
KR100531969B1
KR100531969B1 KR10-1999-7009125A KR19997009125A KR100531969B1 KR 100531969 B1 KR100531969 B1 KR 100531969B1 KR 19997009125 A KR19997009125 A KR 19997009125A KR 100531969 B1 KR100531969 B1 KR 100531969B1
Authority
KR
South Korea
Prior art keywords
carbon atoms
amino
carbonitrile
cyano
phenylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR10-1999-7009125A
Other languages
English (en)
Korean (ko)
Other versions
KR20010006047A (ko
Inventor
위스너알란
존슨버나드딘
라이크마빈프레드
플로이드미들톤브라우너2세
키첸더글라스비.
초우훼이-류
Original Assignee
와이어쓰 홀딩스 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 와이어쓰 홀딩스 코포레이션 filed Critical 와이어쓰 홀딩스 코포레이션
Publication of KR20010006047A publication Critical patent/KR20010006047A/ko
Application granted granted Critical
Publication of KR100531969B1 publication Critical patent/KR100531969B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
KR10-1999-7009125A 1997-04-03 1998-04-02 치환된 3-시아노 퀴놀린, 이를 함유하는 약제학적 조성물 및 이의 제조방법 Expired - Lifetime KR100531969B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US82660497A 1997-04-03 1997-04-03
US8/826,604 1997-04-03
US08/826,604 1997-04-03
PCT/US1998/006480 WO1998043960A1 (en) 1997-04-03 1998-04-02 Substituted 3-cyano quinolines

Publications (2)

Publication Number Publication Date
KR20010006047A KR20010006047A (ko) 2001-01-15
KR100531969B1 true KR100531969B1 (ko) 2005-11-30

Family

ID=25247041

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-1999-7009125A Expired - Lifetime KR100531969B1 (ko) 1997-04-03 1998-04-02 치환된 3-시아노 퀴놀린, 이를 함유하는 약제학적 조성물 및 이의 제조방법

Country Status (26)

Country Link
EP (1) EP0973746B1 (enExample)
JP (2) JP4537500B2 (enExample)
KR (1) KR100531969B1 (enExample)
CN (1) CN1121391C (enExample)
AR (1) AR012313A1 (enExample)
AT (1) ATE250583T1 (enExample)
AU (1) AU750906B2 (enExample)
BR (1) BR9808478A (enExample)
CA (1) CA2285241C (enExample)
CZ (1) CZ299136B6 (enExample)
DE (1) DE69818442T2 (enExample)
DK (1) DK0973746T3 (enExample)
ES (1) ES2209124T3 (enExample)
HU (1) HU229549B1 (enExample)
IL (1) IL132192A0 (enExample)
NO (1) NO313827B1 (enExample)
NZ (1) NZ337782A (enExample)
PL (1) PL196471B1 (enExample)
PT (1) PT973746E (enExample)
RU (1) RU2202551C2 (enExample)
SK (1) SK284922B6 (enExample)
TR (1) TR199902946T2 (enExample)
TW (1) TWI228492B (enExample)
UA (1) UA73073C2 (enExample)
WO (1) WO1998043960A1 (enExample)
ZA (1) ZA982771B (enExample)

Families Citing this family (379)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2263479A1 (en) 1996-09-25 1998-04-02 Zeneca Limited Quinoline derivatives inhibiting the effect of growth factors such as vegf
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6294532B1 (en) 1997-08-22 2001-09-25 Zeneca Limited Oxindolylquinazoline derivatives as angiogenesis inhibitors
HRP20010119B1 (hr) 1998-08-18 2008-05-31 The Regents Of The University Of California Sprječavanje stvaranja sluzi u dišnim putevima primjenom antagonista egf-r
US6288082B1 (en) 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
NZ510551A (en) * 1998-09-29 2003-03-28 American Cyanamid Co Substituted 3-cyanoquinolines useful as protein tyrosine kinases inhibitors
DK2253620T3 (da) 1998-09-29 2014-03-31 Wyeth Holdings Llc Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
AU2004200300A1 (en) * 1998-09-29 2004-02-19 Wyeth Holdings Corporation Substituted 3-cyanoquinolines as Protein Tyrosine Kinases Inhibitors
GB9904103D0 (en) 1999-02-24 1999-04-14 Zeneca Ltd Quinoline derivatives
CZ20013079A3 (cs) * 1999-02-27 2001-11-14 Boehringer Ingelheim Pharma Kg Deriváty 4-aminochinazolinu a chinolinu
RU2001131356A (ru) * 1999-04-21 2003-06-27 Американ Цианамид Компани (US) Замещенные 3-циано-[1.7], [1.5] и [1.8] нафтиридиновые ингибиторы тирозинкиназ
US6355636B1 (en) 1999-04-21 2002-03-12 American Cyanamid Company Substituted 3-cyano-[1.7],[1.5], and [1.8] naphthyridine inhibitors of tyrosine kinases
US6548496B2 (en) 1999-04-21 2003-04-15 American Cyanamid Company Substituted 3-cyano-[1.7], [1.5], and [1.8] naphthyridine inhibitors of tyrosine kinases
GB9910580D0 (en) * 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB9910577D0 (en) * 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB9910579D0 (en) * 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
SK287010B6 (sk) * 1999-06-21 2009-09-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyklické heterocyklické zlúčeniny, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a ich použitie
US7192698B1 (en) 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
US6927203B1 (en) 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
JP3522727B2 (ja) 1999-11-05 2004-04-26 アストラゼネカ アクチボラグ Ｖｅｇｆ阻害剤としてのキナゾリン誘導体
US6638929B2 (en) 1999-12-29 2003-10-28 Wyeth Tricyclic protein kinase inhibitors
CN100432055C (zh) * 1999-12-29 2008-11-12 惠氏公司 三环蛋白激酶抑制剂
US6384051B1 (en) 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
BR0109165A (pt) * 2000-03-13 2003-04-22 American Cyanamid Co Método de tratamento de pólipos colÈnicos
AR035851A1 (es) * 2000-03-28 2004-07-21 Wyeth Corp 3-cianoquinolinas, 3-ciano-1,6-naftiridinas y 3-ciano-1,7-naftiridinas como inhibidoras de proteina quinasas
US6608048B2 (en) 2000-03-28 2003-08-19 Wyeth Holdings Tricyclic protein kinase inhibitors
US6521618B2 (en) 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
DE60121931T2 (de) 2000-04-07 2007-03-01 Astrazeneca Ab Chinazolinverbindungen
US6627634B2 (en) 2000-04-08 2003-09-30 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
MXPA02009855A (es) * 2000-04-08 2003-03-27 Boehringer Ingelheim Pharma Heterociclos biciclicos, medicamentos que contienen estos compuestos, su empleo y procedimientos para su preparacion.
AU2002216758A1 (en) * 2000-07-03 2002-01-14 Astrazeneca Ab Quinazolines with therapeutic use
US6576644B2 (en) * 2000-09-06 2003-06-10 Bristol-Myers Squibb Co. Quinoline inhibitors of cGMP phosphodiesterase
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
JP2004517059A (ja) 2000-11-02 2004-06-10 アストラゼネカ アクチボラグ 抗腫瘍剤用の４−置換キノリン類
WO2002044166A1 (en) 2000-11-02 2002-06-06 Astrazeneca Ab Substituted quinolines as antitumor agents
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
CN100457719C (zh) * 2000-12-29 2009-02-04 惠氏公司 区域选择性制备取代的苯并[g]喹啉-3-腈和苯并[g]喹唑啉的方法
SE0101675D0 (sv) * 2001-05-11 2001-05-11 Astrazeneca Ab Novel composition
WO2003000266A1 (en) * 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel quinolines and uses thereof
EP1412367A4 (en) 2001-06-21 2006-05-03 Ariad Pharma Inc NEW CHINOLINE AND ITS USE
EP1409481B1 (en) 2001-07-16 2006-10-04 Astrazeneca AB Quinoline derivatives and their use as tyrosine kinase inhibitors
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
WO2003050090A1 (en) * 2001-11-27 2003-06-19 Wyeth Holdings Corporation 3-cyanoquinolines as inhibitors of egf-r and her2 kinases
AU2002347336A1 (en) * 2001-12-05 2003-06-17 Astrazeneca Ab Quinoline derivatives
WO2003047582A1 (en) * 2001-12-05 2003-06-12 Astrazeneca Ab Quinoline derivatives as antitumour agents
GB0129099D0 (en) * 2001-12-05 2002-01-23 Astrazeneca Ab Chemical compounds
AU2002347359A1 (en) * 2001-12-05 2003-06-17 Astrazeneca Ab Quinoline derivatives
EP1477481B1 (en) 2002-01-28 2009-07-22 Ube Industries, Ltd. Process for producing quinazolin-4-one derivative
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
PL401638A1 (pl) 2002-03-13 2013-05-27 Array Biopharma Inc. N3 alkilowane pochodne benzimidazolu jako inhibitory MEK
TWI275390B (en) * 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
JP2005536462A (ja) * 2002-04-30 2005-12-02 ユン ジン ファーマスーチカル インダストリーズ カンパニー リミテッド カスパーゼ−３阻害剤としてのキノリン誘導体、この製造方法及びこれを含む薬剤学的組成物
US20050276812A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
DE10221018A1 (de) 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
EP2263691B1 (en) 2002-07-15 2012-08-29 F.Hoffmann-La Roche Ag Treatment of cancer with the recombinant humanized monoclonal anti-erbb2 antibody 2C4 (rhuMAb 2C4)
CA2491191C (en) 2002-07-15 2014-02-04 Exelixis, Inc. Receptor-type kinase modulators and methods of use
KR100980065B1 (ko) 2002-09-27 2010-09-03 젠코어 인코포레이티드 최적화된 Ｆｃ 변이체 및 그의 제조 방법
GB0225579D0 (en) * 2002-11-02 2002-12-11 Astrazeneca Ab Chemical compounds
WO2004060400A1 (ja) * 2003-01-06 2004-07-22 Mitsubishi Pharma Corp 上皮成長因子受容体を分子標的とする抗精神病薬
CL2004000016A1 (es) * 2003-01-21 2005-04-15 Wyeth Corp Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina.
WO2004069250A1 (en) * 2003-02-03 2004-08-19 Astrazeneca Ab 3-cyano-quinoline derivatives as non-receptor tyrosine kinase inhibitors
WO2004069249A1 (en) * 2003-02-03 2004-08-19 Astrazeneca Ab 3-cyano-quinoline derivatives as non-receptor tyrosine kinase inhibitors
WO2004069827A1 (en) * 2003-02-03 2004-08-19 Astrazeneca Ab Quinoline derivatives and use thereof as antitumor agents
US7223749B2 (en) 2003-02-20 2007-05-29 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
CA2518898A1 (en) 2003-03-12 2004-09-23 Vasgene Therapeutics, Inc. Nucleic acid compounds for inhibiting angiogenesis and tumor growth
US7381410B2 (en) 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
UA80607C2 (en) * 2003-04-09 2007-10-10 White Holdings Corp Process for the preparation of 3-cyano-6-alkoxy-7-nitro-4-quinolines
WO2004108703A1 (en) * 2003-06-05 2004-12-16 Astrazeneca Ab Pyrazinyl 3-cyanoquinoline derivatives for use in the treatment of tumours
WO2004108704A1 (en) * 2003-06-05 2004-12-16 Astrazeneca Ab Pyrimidin-4-yl 3-cyanoquinoline derivatives for use in the treatment of tumours
KR101218213B1 (ko) 2003-07-03 2013-01-04 시토비아 인크. 카스파제의 활성인자 및 세포자멸사의 유도인자로서의4-아릴아미노-퀴나졸린
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
DK1663982T3 (da) * 2003-07-31 2008-03-17 Sanofi Aventis Aminoquinolinderivater og deres anvendelse som adenosin-A3-ligander
RU2317290C2 (ru) * 2003-07-31 2008-02-20 Санофи-Авентис Производные аминохинолина и их применение в качестве лигандов аденозина а3
BRPI0413667A (pt) * 2003-08-19 2006-10-24 Wyeth Corp Processo para a preparação de 4-amino-3-carbonitrilas de quinolina
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7399865B2 (en) * 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
CA2744997A1 (en) 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and method of use
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US7456189B2 (en) 2003-09-30 2008-11-25 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
DE10349113A1 (de) 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Aminocrotonylverbindungen
AU2003291245A1 (en) * 2003-11-06 2004-06-06 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
SG149815A1 (en) 2003-11-06 2009-02-27 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
ATE495155T1 (de) 2003-11-19 2011-01-15 Array Biopharma Inc Heterocyclische inhibitoren von mek
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
NZ547327A (en) 2003-11-21 2009-08-28 Array Biopharma Inc AKT protein kinase inhibitors
UA83881C2 (en) 2003-12-18 2008-08-26 Янссен Фармацевтика Н.В. Pyrido- and pyrimidopyrimidine derivatives as anti-proliferative agents
UA83880C2 (en) * 2003-12-18 2008-08-26 Янссен Фармацевтика Н.В. 3-cyano-quinoline derivatives with antiproliferative activity
SG149817A1 (en) * 2004-01-16 2009-02-27 Wyeth Corp Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof
SE0400284D0 (sv) * 2004-02-10 2004-02-10 Astrazeneca Ab Novel compounds
TW200529846A (en) 2004-02-20 2005-09-16 Wyeth Corp 3-quinolinecarbonitrile protein kinase inhibitors
CA2559554A1 (en) 2004-03-12 2005-09-29 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
KR20120123619A (ko) 2004-03-12 2012-11-08 바스진 테라퓨틱스, 인크. 혈관형성 및 종양 성장을 억제하기 위한 폴리펩티드 화합물
DK2439285T3 (da) 2004-03-31 2019-07-29 Massachusetts Gen Hospital Fremgangsmåde til at bestemme reaktivitet af cancer på behandlinger målrettet mod epidermal vækstfaktor-receptor
EP1746999B1 (en) 2004-05-06 2011-11-16 Warner-Lambert Company LLC 4-phenylamino-quinazolin-6-yl-amides
EP2940043A1 (en) 2004-07-15 2015-11-04 Xencor, Inc. Optimized fc variants
WO2006034455A2 (en) 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
CA2582247C (en) 2004-10-20 2014-02-11 Applied Research Systems Ars Holding N.V. 3-arylamino pyridine derivatives
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EP2314618A3 (en) 2004-11-12 2011-10-19 Xencor Inc. Fc variants with altered binding to FcRn
HUP0402371A2 (en) * 2004-11-15 2006-09-28 Sanofi Aventis Novel 125-i-labeled amino-quinoline derivatives
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
KR20200058588A (ko) 2005-01-21 2020-05-27 제넨테크, 인크. Ｈｅｒ 항체의 고정 용량 투여법
ZA200706804B (en) 2005-02-03 2008-10-29 Gen Hospital Corp Method for treating gefitinib resistant cancer
MY152164A (en) 2005-02-23 2014-08-15 Genentech Inc Extending time to disease progression or survival in cancer patients
AU2006247520A1 (en) * 2005-05-18 2006-11-23 Wyeth 3-cyanoquinoline inhibitors of TPL2 kinase and methods of making and using the same
TW201238952A (en) 2005-05-18 2012-10-01 Array Biopharma Inc Heterocyclic inhibitors of MEK and methods of use thereof
RU2007143161A (ru) * 2005-05-25 2009-07-10 Вайет (Us) Способы синтеза замещенных 3-цианохинов и их продуктов
AU2006268227A1 (en) 2005-07-08 2007-01-18 Xencor, Inc Optimized anti-Ep-CAM antibodies
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
AU2006306991A1 (en) 2005-10-28 2007-05-03 Takeda Pharmaceutical Company Limited Heterocyclic amide compound and use thereof
CA2626326C (en) 2005-11-04 2021-02-16 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
JP5688877B2 (ja) 2005-11-11 2015-03-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌疾患の治療用キナゾリン誘導体
WO2007089646A1 (en) 2006-01-31 2007-08-09 Array Biopharma Inc. Kinase inhibitors and methods of use thereof
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
ATE532789T1 (de) 2006-07-06 2011-11-15 Array Biopharma Inc Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
CN101511842B (zh) 2006-07-06 2012-10-31 阵列生物制药公司 作为akt蛋白激酶抑制剂的二氢呋喃并嘧啶
CA2656618C (en) 2006-07-06 2014-08-26 Array Biopharma Inc. Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
EA014779B1 (ru) 2006-07-13 2011-02-28 Янссен Фармацевтика Н.В. Производные хиназолина в качестве mtki
ES2402591T3 (es) 2006-08-14 2013-05-07 Xencor Inc. Anticuerpos optimizados que seleccionan como diana CD19
EP2845912A1 (en) 2006-09-12 2015-03-11 Genentech, Inc. Methods and compositions for the diagnosis and treatment of lung cancer using KIT gene as genetic marker
CA2663599A1 (en) 2006-09-18 2008-03-27 Boehringer Ingelheim International Gmbh Method for treating cancer harboring egfr mutations
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
AU2008212999A1 (en) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
KR20150039212A (ko) 2007-03-02 2015-04-09 제넨테크, 인크. 낮은 ｈｅｒ３ 발현을 기초로 한 ｈｅｒ 이량체화 억제제에 대한 반응 예측
ES2659517T3 (es) 2007-05-30 2018-03-16 Xencor, Inc. Métodos y composiciones para inhibir células que expresan CD32B
SI2171090T1 (sl) 2007-06-08 2013-07-31 Genentech, Inc. Markerji genskega izraĹľanja tumorske odpornosti na HER2 inhibitorsko zdravljenje
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
WO2009006567A2 (en) 2007-07-05 2009-01-08 Array Biopharma Inc. Pyrimidyl cyclopentanes as akt protein kinase inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
SI2173723T1 (sl) 2007-07-05 2011-12-30 Array Biopharma Inc Pirimidil ciklopentani kot inhibitorji AKT-protein-kinaze
CA2693715C (en) 2007-07-27 2015-10-27 Janssen Pharmaceutica Nv Pyrrolopyrimidines
EP2185594B1 (en) 2007-08-13 2016-04-06 VasGene Therapeutics, Inc. Cancer treatment using humanized antibodies that bind to ephb4
CN101148439B (zh) * 2007-09-14 2011-06-22 东南大学 一种吉非替尼的制备方法
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
KR101616758B1 (ko) 2007-12-26 2016-04-29 젠코어 인코포레이티드 ＦｃＲｎ에 대한 변경된 결합성을 갖는 Ｆｃ 변이체
NZ586346A (en) 2008-01-09 2012-02-24 Array Biopharma Inc Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
WO2009089453A1 (en) 2008-01-09 2009-07-16 Array Biopharma Inc. Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
EP2245026B1 (de) 2008-02-07 2012-08-01 Boehringer Ingelheim International GmbH Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
DE102008009609A1 (de) 2008-02-18 2009-08-20 Freie Universität Berlin Substituierte 4-(Indol-3-yl)chinazoline und deren Verwendung und Herstellung
US12492253B1 (en) 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies
NZ589143A (en) 2008-05-14 2012-02-24 Genomic Health Inc Colorectal cancer response prediction based on AREG EREG DUSP6 and SLC26A3 expression levels
DK2310011T3 (da) 2008-06-17 2013-10-14 Wyeth Llc Antineoplastiske kombinationer indeholdende hki-272 og vinorelbin
CA2730715C (en) 2008-08-04 2013-10-01 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
MX2011001127A (es) 2008-08-04 2011-03-21 Merck Patent Gmbh Compuestos novedosos de fenilamino-isonicotinamida.
CA2733153C (en) 2008-08-08 2016-11-08 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
CA2742945A1 (en) 2008-11-10 2010-05-14 Bayer Schering Pharma Aktiengesellschaft Substituted sulphonamido phenoxybenzamides
JP5590040B2 (ja) 2008-11-12 2014-09-17 アリアド・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害剤としてのピラジノピラジンおよび誘導体
DK2387563T4 (da) 2009-01-16 2022-07-18 Exelixis Inc Malatsalt af n-(4-{ [ 6, 7-bis(methyloxy)quinolin-4-yl]oxy}phenyl-n'-(4-fluorphenyl)cyclopropan-1,1-dicarboxamid, og krystallinske former deraf til behandling af cancer
KR20140036332A (ko) 2009-04-06 2014-03-25 와이어쓰 엘엘씨 네라티닙을 이용한 유방암의 치료법
JP5963672B2 (ja) 2009-07-06 2016-08-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｉｂｗ２９９２、その塩及びこの活性成分を含む固体医薬製剤の乾燥方法
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CN102020639A (zh) * 2009-09-14 2011-04-20 上海恒瑞医药有限公司 6-氨基喹唑啉或3-氰基喹啉类衍生物、其制备方法及其在医药上的应用
CA2777304A1 (en) 2009-10-21 2011-04-28 Marion Hitchcock Substituted benzosulphonamides
WO2011047795A1 (en) 2009-10-21 2011-04-28 Bayer Schering Pharma Aktiengesellschaft Substituted benzosulphonamides
JP2013508320A (ja) 2009-10-21 2013-03-07 バイエル・ファルマ・アクチェンゲゼルシャフト 置換されたハロフェノキシベンズアミド誘導体
JP6184695B2 (ja) 2009-12-04 2017-08-23 ジェネンテック， インコーポレイテッド 多重特異性抗体、抗体アナログ、組成物、及び方法
EP2523957A1 (en) 2010-01-12 2012-11-21 F. Hoffmann-La Roche AG Tricyclic heterocyclic compounds, compositions and methods of use thereof
JP2013521487A (ja) 2010-03-04 2013-06-10 カルペン，オッリ Ｅｇｆｒ阻害剤を用いる処置のための患者を選択する方法
RU2012141536A (ru) 2010-03-17 2014-04-27 Ф. Хоффманн-Ля Рош Аг Имидазопиридины, композиции и способы применения
BR112012024489A2 (pt) 2010-03-29 2016-05-31 Zymeworks Inc anticorpos com função efetora suprimida ou aumentada
CN103038643A (zh) 2010-04-16 2013-04-10 基因泰克公司 作为pi3k/akt激酶途径抑制剂效能的预测性生物标记的foxo3a
US20130053375A1 (en) * 2010-05-07 2013-02-28 Glaxo Group Limited Amino-quinolines as kinase inhibitors
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
KR101562347B1 (ko) * 2010-06-09 2015-10-22 티안진 헤메이 바이오-텍 컴퍼니 리미티드 시아노퀴놀린 유도체
CA2805148C (en) * 2010-07-14 2016-01-19 Zhejiang Beta Pharma Inc. Novel fused heterocyclic derivatives useful as c-met tyrosine kinase inhibitors
UY33549A (es) * 2010-08-10 2012-01-31 Glaxo Group Ltd Quinolil aminas como agentes inhibidores de las quinasas
CN103209695A (zh) 2010-09-15 2013-07-17 弗·哈夫曼-拉罗切有限公司 氮杂苯并噻唑化合物、组合物及应用方法
EP2632899A1 (en) 2010-10-29 2013-09-04 Bayer Intellectual Property GmbH Substituted phenoxypyridines
US9309322B2 (en) 2010-11-12 2016-04-12 Scott & White Healthcare (Swh) Antibodies to tumor endothelial marker 8
KR20140009259A (ko) 2010-11-19 2014-01-22 에프. 호프만-라 로슈 아게 피라졸로피리딘 및 tyk2 억제제로서 이의 용도
WO2012085176A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
EA023998B1 (ru) 2011-03-04 2016-08-31 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Аминохинолины в качестве ингибиторов киназ
WO2012122513A2 (en) 2011-03-10 2012-09-13 Omeros Corporation Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution
CN102675287A (zh) * 2011-03-11 2012-09-19 江苏恒瑞医药股份有限公司 (e)-n-[4-[[3-氯-4-(2-吡啶基甲氧基)苯基]氨基]-3-氰基-7-乙氧基-6-喹啉基]-3-[(2r)-1-甲基吡咯烷-2-基]丙-2-烯酰胺的可药用的盐、其制备方法及其在医药上的应用
ES2620644T3 (es) 2011-04-01 2017-06-29 Genentech, Inc. Combinaciones de compuestos inhibidores de AKT y agentes quimioterapéuticos, y métodos de uso
RU2013148817A (ru) 2011-04-01 2015-05-10 Дженентек, Инк. Комбинации соединений-ингибиторов акт и мек и способы их применения
WO2012160130A1 (en) 2011-05-25 2012-11-29 Universite Paris Descartes Erk inhibitors for use in treating spinal muscular atrophy
WO2013007768A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
WO2013007765A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
JP5855253B2 (ja) 2011-08-12 2016-02-09 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ インダゾール化合物、組成物及び使用方法
AU2012295394B2 (en) 2011-08-12 2016-04-14 Omeros Corporation Anti-FZD10 monoclonal antibodies and methods for their use
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
WO2013041539A1 (en) 2011-09-20 2013-03-28 F. Hoffmann-La Roche Ag Imidazopyridine compounds, compositions and methods of use
AU2012331289B2 (en) 2011-11-04 2017-07-13 F. Hoffmann-La Roche Ag New aryl-quinoline derivatives
CN103204822B (zh) 2012-01-17 2014-12-03 上海科州药物研发有限公司 作为蛋白激酶抑制剂的苯并噁唑化合物及其制备方法和用途
CA2866612C (en) 2012-03-08 2018-01-16 Halozyme, Inc. Conditionally active ph-dependent cetuximab variant anti-epidermal growth factor receptor antibodies and method of use thereof
EP2831115A1 (en) 2012-03-27 2015-02-04 F. Hoffmann-La Roche AG Diagnosis and treatments relating to her3 inhibitors
CN103539783A (zh) * 2012-07-12 2014-01-29 江苏恒瑞医药股份有限公司 一种酪氨酸激酶抑制剂的二马来酸盐的i型结晶及制备方法
AR092530A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
TWI592417B (zh) 2012-09-13 2017-07-21 葛蘭素史克智慧財產發展有限公司 胺基喹唑啉激酶抑制劑之前藥
TWI630203B (zh) 2013-02-21 2018-07-21 葛蘭素史克智慧財產發展有限公司 做為激酶抑制劑的喹唑啉類
EP2970307B1 (en) 2013-03-13 2020-03-11 Genentech, Inc. Pyrazolo compounds and uses thereof
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
CN103275001B (zh) * 2013-06-14 2015-02-18 苏州明锐医药科技有限公司 4-氨基-3-喹啉甲腈衍生物的制备方法
EP3041474B1 (en) 2013-09-05 2020-03-18 Genentech, Inc. Antiproliferative compounds
EP3043822A1 (en) 2013-09-11 2016-07-20 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Compositions for preparing cardiomyocytes
WO2015038984A2 (en) 2013-09-12 2015-03-19 Halozyme, Inc. Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
NZ714555A (en) 2013-09-17 2020-03-27 Obi Pharma Inc Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment
WO2015049325A1 (en) 2013-10-03 2015-04-09 F. Hoffmann-La Roche Ag Therapeutic inhibitors of cdk8 and uses thereof
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
BR112016013963A2 (pt) 2013-12-17 2017-10-10 Genentech Inc terapia de combinação compreendendo agonistas de ligação de ox40 e antagonistas de ligação do eixo de pd-1
JP6841656B2 (ja) 2013-12-17 2021-03-10 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニスト及びタキサンを使用する癌の治療方法
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
AU2015206603B9 (en) 2014-01-14 2019-07-18 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using PD-L1 isoforms
CA2943834A1 (en) 2014-03-31 2015-10-08 Genentech, Inc. Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
HRP20192285T1 (hr) 2014-03-31 2020-03-06 F. Hoffmann - La Roche Ag Anti-ox40 protutijela i postupci uporabe
CN107074823B (zh) 2014-09-05 2021-05-04 基因泰克公司 治疗性化合物及其用途
EP3193866A1 (en) 2014-09-19 2017-07-26 Genentech, Inc. Use of cbp/ep300 and bet inhibitors for treatment of cancer
WO2016057367A1 (en) 2014-10-06 2016-04-14 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
JP6783230B2 (ja) 2014-10-10 2020-11-11 ジェネンテック， インコーポレイテッド ヒストンデメチラーゼのインヒビターとしてのピロリドンアミド化合物
WO2016073380A1 (en) 2014-11-03 2016-05-12 Genentech, Inc. Method and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
BR112017009151A2 (pt) 2014-11-03 2018-03-06 Genentech, Inc. ensaios para detectar subgrupos imunológicos de célula t e métodos de uso dos mesmos
CN107073126A (zh) 2014-11-06 2017-08-18 豪夫迈·罗氏有限公司 包含ox40结合激动剂和tigit抑制剂的组合疗法
MA40943A (fr) 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
JP6639497B2 (ja) 2014-11-10 2020-02-05 ジェネンテック， インコーポレイテッド ブロモドメインインヒビターおよびその使用
MA40940A (fr) 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
KR20170096112A (ko) 2014-11-17 2017-08-23 제넨테크, 인크. Ox40 결합 효능제 및 pd-1 축 결합 길항제를 포함하는 조합 요법
WO2016086200A1 (en) 2014-11-27 2016-06-02 Genentech, Inc. 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
CA2968359A1 (en) 2014-12-23 2016-06-30 Genentech, Inc. Compositions and methods for treating and diagnosing chemotherapy-resistant cancers
WO2016109546A2 (en) 2014-12-30 2016-07-07 Genentech, Inc. Methods and compositions for prognosis and treatment of cancers
WO2016112251A1 (en) 2015-01-09 2016-07-14 Genentech, Inc. 4,5-dihydroimidazole derivatives and their use as histone demethylase (kdm2b) inhibitors
CN107406429B (zh) 2015-01-09 2021-07-06 基因泰克公司 哒嗪酮衍生物及其在治疗癌症中的用途
WO2016112284A1 (en) 2015-01-09 2016-07-14 Genentech, Inc. (piperidin-3-yl)(naphthalen-2-yl)methanone derivatives and related compounds as inhibitors of the histone demethylase kdm2b for the treatment of cancer
JP6709792B2 (ja) 2015-01-29 2020-06-17 ジェネンテック， インコーポレイテッド 治療用化合物およびその使用
JP6636031B2 (ja) 2015-01-30 2020-01-29 ジェネンテック， インコーポレイテッド 治療用化合物およびその使用
MA41598A (fr) 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
MA41866A (fr) 2015-03-31 2018-02-06 Massachusetts Gen Hospital Molécules à auto-assemblage pour l'administration ciblée de médicaments
WO2016164480A1 (en) 2015-04-07 2016-10-13 Genentech, Inc. Antigen binding complex having agonistic activity and methods of use
EP3280708B1 (en) * 2015-04-10 2021-09-01 Araxes Pharma LLC Substituted quinazoline compounds and methods of use thereof
PT3294770T (pt) 2015-05-12 2020-12-04 Hoffmann La Roche Métodos terapêuticos e diagnósticos para o cancro
PL3303632T5 (pl) 2015-05-29 2023-07-03 F. Hoffmann-La Roche Ag Terapeutyczne i diagnostyczne sposoby stosowane w nowotworze
AU2016274585A1 (en) 2015-06-08 2017-12-14 Genentech, Inc. Methods of treating cancer using anti-OX40 antibodies
MX2017015937A (es) 2015-06-08 2018-12-11 Genentech Inc Métodos de tratamiento del cáncer con anticuerpos anti-ox40 y antagonistas de unión al eje de pd-1.
WO2016205320A1 (en) 2015-06-17 2016-12-22 Genentech, Inc. Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
IL293770B2 (en) 2015-07-06 2023-07-01 Gilead Sciences Inc Modulators of cot and methods of using them
MX2017017124A (es) 2015-07-06 2018-03-09 Gilead Sciences Inc 6-amino-quinolin-3-carbonitrilos como moduladores de cancer osaka tiroides (cot).
ES2862727T3 (es) 2015-08-26 2021-10-07 Fundacion Del Sector Publico Estatal Centro Nac De Investigaciones Oncologicas Carlos Iii F S P Cnio Compuestos tricíclicos condensados como inhibidores de proteínas quinasas
AR105910A1 (es) 2015-09-04 2017-11-22 Obi Pharma Inc Matrices de glicano y método de uso
SI3353210T1 (sl) 2015-09-25 2025-03-31 F. Hoffmann-La Roche Ag Protitelesa proti TIGIT in postopki uporabe
EP3356349A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3356359B1 (en) 2015-09-28 2021-10-20 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058728A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058902A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10875842B2 (en) 2015-09-28 2020-12-29 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3356354A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
BR112018006873A2 (pt) 2015-10-05 2018-11-06 The Trustees Of Columbia University In The City Of New York ativadores do fluxo autofágico e fosfolipase d e depuração de agregados de proteína incluindo tau e tratamento de proteinopatias
EA038635B9 (ru) 2015-11-16 2021-10-26 Араксис Фарма Ллк 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
DK3389662T3 (da) 2015-12-16 2022-02-28 Genentech Inc Fremgangsmåde til fremstilling af tricykliske PI3K-inhibitorforbindelser og fremgangsmåder til anvendelse af disse til behandling af cancer
AU2017205089B2 (en) 2016-01-08 2023-10-05 F. Hoffmann-La Roche Ag Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies
CN114395624A (zh) 2016-02-29 2022-04-26 基因泰克公司 用于癌症的治疗和诊断方法
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
EP3436482A4 (en) 2016-03-29 2020-03-11 OBI Pharma, Inc. ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND METHODS
WO2017181079A2 (en) 2016-04-15 2017-10-19 Genentech, Inc. Methods for monitoring and treating cancer
CN109072311A (zh) 2016-04-15 2018-12-21 豪夫迈·罗氏有限公司 用于癌症的诊断和治疗方法
ES2850428T3 (es) 2016-04-15 2021-08-30 Hoffmann La Roche Procedimientos de monitorización y tratamiento del cáncer
CA3021548A1 (en) 2016-04-22 2017-10-26 Obi Pharma, Inc. Cancer immunotherapy by immune activation or immune modulation via globo series antigens
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
CN115028617A (zh) 2016-05-24 2022-09-09 基因泰克公司 Cbp/ep300的杂环抑制剂及其在治疗癌症中的用途
JP7014736B2 (ja) 2016-05-24 2022-02-01 ジェネンテック， インコーポレイテッド がんの処置のためのピラゾロピリジン誘導体
EP4371570A3 (en) 2016-06-08 2024-07-17 Xencor, Inc. Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
WO2017214373A1 (en) 2016-06-08 2017-12-14 Genentech, Inc. Diagnostic and therapeutic methods for cancer
ES2800339T3 (es) 2016-06-30 2020-12-29 Gilead Sciences Inc 4,6-diaminoquinazolinas como moduladores de cuna y métodos de uso de los mismos
WO2018022933A1 (en) 2016-07-27 2018-02-01 Obi Pharma, Inc. Immunogenic/therapeutic glycan compositions and uses thereof
KR102528998B1 (ko) 2016-07-29 2023-05-03 오비아이 파머 인코퍼레이티드 인간 항체, 제약 조성물 및 방법
EP3494139B1 (en) 2016-08-05 2022-01-12 F. Hoffmann-La Roche AG Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
CN109476748B (zh) 2016-08-08 2023-05-23 豪夫迈·罗氏有限公司 用于癌症的治疗和诊断方法
WO2018064510A1 (en) 2016-09-29 2018-04-05 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
AU2017339517B2 (en) 2016-10-06 2024-03-14 Foundation Medicine, Inc. Therapeutic and diagnostic methods for cancer
JP2019535250A (ja) 2016-10-29 2019-12-12 ジェネンテック， インコーポレイテッド 抗ｍｉｃ抗体及び使用方法
CN110290800A (zh) 2016-11-21 2019-09-27 台湾浩鼎生技股份有限公司 缀合生物分子、医药组合物及方法
WO2018140514A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
US11059819B2 (en) 2017-01-26 2021-07-13 Janssen Biotech, Inc. Fused hetero-hetero bicyclic compounds and methods of use thereof
US11274093B2 (en) 2017-01-26 2022-03-15 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
US11279689B2 (en) 2017-01-26 2022-03-22 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
EP3573964A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Benzothiophene and benzothiazole compounds and methods of use thereof
WO2018160841A1 (en) 2017-03-01 2018-09-07 Genentech, Inc. Diagnostic and therapeutic methods for cancer
EP3609537A1 (en) 2017-04-13 2020-02-19 H. Hoffnabb-La Roche Ag An interleukin-2 immunoconjugate, a cd40 agonist, and optionally a pd-1 axis binding antagonist for use in methods of treating cancer
CN110831933A (zh) 2017-05-25 2020-02-21 亚瑞克西斯制药公司 喹唑啉衍生物作为突变kras、hras或nras的调节剂
EP3630745A2 (en) 2017-05-25 2020-04-08 Araxes Pharma LLC Covalent inhibitors of kras
JP2020521741A (ja) 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー がんの処置のための化合物およびその使用の方法
CN111492245A (zh) 2017-07-21 2020-08-04 基因泰克公司 癌症的治疗和诊断方法
JP2020530297A (ja) 2017-08-11 2020-10-22 ジェネンテック， インコーポレイテッド 抗ｃｄ８抗体及びその使用
WO2019051296A1 (en) 2017-09-08 2019-03-14 Genentech, Inc. DIAGNOSTIC AND THERAPEUTIC METHODS OF CANCER
EP3710001B1 (en) 2017-10-27 2025-06-18 University Of Virginia Patent Foundation Compounds and methods for regulating, limiting, or inhibiting avil expression
WO2019090263A1 (en) 2017-11-06 2019-05-09 Genentech, Inc. Diagnostic and therapeutic methods for cancer
EP3740756A4 (en) 2018-01-15 2021-10-27 Epiaxis Therapeutics Pty Ltd AGENTS AND METHODS FOR PREDICTING THE THERAPEUTIC RESPONSE
WO2019148043A1 (en) 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
SG11202006921PA (en) 2018-01-26 2020-08-28 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
CR20250117A (es) 2018-01-26 2025-05-09 Exelixis Inc COMPUESTOS PARA EL TRATAMIENTO DE TRASTORNOS DEPENDIENTES DE CINASAS (Divisional 2020-0355)
MX2020008882A (es) 2018-02-26 2021-01-08 Genentech Inc Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
EP3797173A2 (en) 2018-05-21 2021-03-31 Nanostring Technologies, Inc. Molecular gene signatures and methods of using same
MA52968A (fr) 2018-06-23 2021-04-28 Hoffmann La Roche Méthodes de traitement du cancer du poumon à l'aide d'un antagoniste de liaison à l'axe pd-1, d'un agent de platine et d'un inhibiteur de la topoisomérase ii
WO2020006176A1 (en) 2018-06-27 2020-01-02 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use
CN108752248A (zh) * 2018-07-17 2018-11-06 常州大学 一种合成1-(3-乙氧基-4-甲氧基)苯基-2-甲磺酰基乙胺的方法
KR20210034622A (ko) 2018-07-18 2021-03-30 제넨테크, 인크. Pd-1 축 결합 길항제, 항 대사제, 및 백금 제제를 이용한 폐암 치료 방법
BR112021001709A2 (pt) 2018-08-01 2021-05-04 Araxes Pharma Llc compostos espiro heterocíclicos e métodos de uso dos mesmos para o tratamento de câncer
EP3847154A1 (en) 2018-09-03 2021-07-14 F. Hoffmann-La Roche AG Carboxamide and sulfonamide derivatives useful as tead modulators
MX2021003214A (es) 2018-09-19 2021-05-12 Genentech Inc Metodos terapeuticos y de diagnostico para el cancer de vejiga.
PL3857230T3 (pl) 2018-09-21 2023-10-16 F. Hoffmann-La Roche Ag Sposoby diagnostyczne dla potrójnie ujemnego raka piersi
EP3867405A4 (en) 2018-10-17 2022-07-20 The University of Queensland Epigenetic biomarker and uses therefor
CN113196061A (zh) 2018-10-18 2021-07-30 豪夫迈·罗氏有限公司 肉瘤样肾癌的诊断和治疗方法
WO2020163589A1 (en) 2019-02-08 2020-08-13 Genentech, Inc. Diagnostic and therapeutic methods for cancer
AU2020228383A1 (en) 2019-02-27 2021-09-23 Genentech, Inc. Dosing for treatment with anti-tigit and anti-CD20 or anti-CD38 antibodies
EP3931565A4 (en) 2019-02-27 2023-04-12 Epiaxis Therapeutics Pty Ltd METHODS AND MEANS OF EVALUATING T-CELL FUNCTION AND PREDICTING RESPONSE TO THERAPY
WO2020223233A1 (en) 2019-04-30 2020-11-05 Genentech, Inc. Prognostic and therapeutic methods for colorectal cancer
JP2022530674A (ja) 2019-05-03 2022-06-30 ジェネンテック， インコーポレイテッド 抗ｐｄ－ｌ１抗体を用いたがんの処置方法
TWI770527B (zh) 2019-06-14 2022-07-11 美商基利科學股份有限公司 Cot 調節劑及其使用方法
CN112300279A (zh) 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 针对抗cd73抗体和变体的方法和组合物
EP4025608A1 (en) 2019-09-04 2022-07-13 F. Hoffmann-La Roche AG Cd8 binding agents and uses thereof
US12371428B2 (en) 2019-09-26 2025-07-29 Exelixis, Inc. Pyridone compounds and methods of use
WO2021062085A1 (en) 2019-09-27 2021-04-01 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2021083949A1 (en) 2019-10-29 2021-05-06 F. Hoffmann-La Roche Ag Bifunctional compounds for the treatment of cancer
EP4055388A1 (en) 2019-11-06 2022-09-14 Genentech, Inc. Diagnostic and therapeutic methods for treatment of hematologic cancers
AU2020381458A1 (en) 2019-11-13 2022-05-12 Genentech, Inc. Therapeutic compounds and methods of use
US11845799B2 (en) 2019-12-13 2023-12-19 Genentech, Inc. Anti-Ly6G6D antibodies and methods of use
AU2020408562A1 (en) 2019-12-20 2022-06-23 Erasca, Inc. Tricyclic pyridones and pyrimidones
WO2021194481A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
KR20220133243A (ko) 2020-01-27 2022-10-04 제넨테크, 인크. 항 tigit 길항제 항체를 이용한 암의 치료 방법
WO2022050954A1 (en) 2020-09-04 2022-03-10 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2021177980A1 (en) 2020-03-06 2021-09-10 Genentech, Inc. Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
JP2023520650A (ja) 2020-03-30 2023-05-18 ギリアード サイエンシーズ， インコーポレイテッド （Ｓ）－６－（（（１－（ビシクロ［１．１．１］ペンタン－１－イル）－１Ｈ－１，２，３－トリアゾール－４－イル）２－メチル－１－オキソ－１，２－ジヒドロイソキノリン－５－イル）メチル）））アミノ）８－クロロ－（ネオペンチルアミノ）キノリン－３－カルボニトリルＣｏｔ阻害剤化合物の固体形態
CN119390681A (zh) 2020-04-02 2025-02-07 吉利德科学公司 用于制备cot抑制剂化合物的方法
CN115698717A (zh) 2020-04-03 2023-02-03 基因泰克公司 癌症的治疗和诊断方法
JP2023523450A (ja) 2020-04-28 2023-06-05 ジェネンテック， インコーポレイテッド 非小細胞肺がん免疫療法のための方法及び組成物
EP4164627A1 (en) 2020-06-16 2023-04-19 Genentech, Inc. Methods and compositions for treating triple-negative breast cancer
US20210395366A1 (en) 2020-06-18 2021-12-23 Genentech, Inc. Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
EP4172628A1 (en) 2020-06-30 2023-05-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery
US20230235408A1 (en) 2020-06-30 2023-07-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies
WO2022006386A1 (en) * 2020-07-02 2022-01-06 Enliven Therapeutics, Inc. Alkyne quinazoline derivatives as inhibitors of erbb2
US11787775B2 (en) 2020-07-24 2023-10-17 Genentech, Inc. Therapeutic compounds and methods of use
CN116568824A (zh) 2020-08-03 2023-08-08 基因泰克公司 淋巴瘤的诊断和治疗方法
WO2022033410A1 (zh) * 2020-08-10 2022-02-17 上海和誉生物医药科技有限公司 一种egfr抑制剂及其制备方法和应用
EP4196612A1 (en) 2020-08-12 2023-06-21 Genentech, Inc. Diagnostic and therapeutic methods for cancer
WO2022047243A1 (en) 2020-08-27 2022-03-03 Enosi Life Sciences Corp. Methods and compositions to treat autoimmune diseases and cancer
WO2022066805A1 (en) 2020-09-23 2022-03-31 Erasca, Inc. Tricyclic pyridones and pyrimidones
CA3193952A1 (en) 2020-10-05 2022-04-14 Bernard Martin Fine Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2022133345A1 (en) 2020-12-18 2022-06-23 Erasca, Inc. Tricyclic pyridones and pyrimidones
CA3210553A1 (en) 2021-02-12 2022-08-18 F. Hoffmann-La Roche Ag Bicyclic tetrahydroazepine derivatives for the treatment of cancer
US20240158393A1 (en) 2021-02-19 2024-05-16 Exelixis, Inc. Pyridone compounds and methods of use
EP4347603A1 (en) 2021-05-25 2024-04-10 Erasca, Inc. Sulfur-containing heteroaromatic tricyclic kras inhibitors
US20240293558A1 (en) 2021-06-16 2024-09-05 Erasca, Inc. Kras inhibitor conjugates
JP2024528697A (ja) 2021-07-20 2024-07-30 エイジーエス・セラピューティクス・ソシエテ・パール・アクシオン・サンプリフィエ 微細藻類由来の細胞外小胞、その調製および使用
TW202321261A (zh) 2021-08-10 2023-06-01 美商伊瑞斯卡公司 選擇性ｋｒａｓ抑制劑
EP4436969A2 (en) 2021-11-24 2024-10-02 Genentech, Inc. Bicyclic therapeutic compounds and methods of use in the treatment of cancer
JP2024541508A (ja) 2021-11-24 2024-11-08 ジェネンテック， インコーポレイテッド 治療用インダゾール化合物およびがんの治療における使用方法
WO2023144127A1 (en) 2022-01-31 2023-08-03 Ags Therapeutics Sas Extracellular vesicles from microalgae, their biodistribution upon administration, and uses
TW202342018A (zh) 2022-03-04 2023-11-01 美商奇奈特生物製藥公司 Mek激酶抑制劑
EP4504780A1 (en) 2022-04-01 2025-02-12 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2023219613A1 (en) 2022-05-11 2023-11-16 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
KR20250022049A (ko) 2022-06-07 2025-02-14 제넨테크, 인크. 항-pd-l1 길항제 및 항-tigit 길항제 항체를 포함하는, 폐암 치료의 효율을 결정하는 방법
CN115057776B (zh) * 2022-06-15 2023-08-22 必维申瓯质量技术服务温州有限公司 2-萘甲酸乙酯衍生物的合成方法
EP4554978A1 (en) 2022-07-13 2025-05-21 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
JP2025523845A (ja) 2022-07-19 2025-07-25 ジェネンテック， インコーポレイテッド 抗ｆｃｒｈ５／抗ｃｄ３二重特異性抗体による処置のための投薬
AR130169A1 (es) 2022-08-11 2024-11-13 Hoffmann La Roche Derivados de tetrahidrotiazepina bicíclicos
CR20250042A (es) 2022-08-11 2025-03-25 Hoffmann La Roche Derivados de tetrahidrotiazepina bicíclicos
CN119677733A (zh) 2022-08-11 2025-03-21 豪夫迈·罗氏有限公司 双环四氢硫氮杂䓬衍生物
TW202417001A (zh) 2022-08-11 2024-05-01 瑞士商赫孚孟拉羅股份公司 雙環四氫吖呯衍生物
JP2025538859A (ja) 2022-10-21 2025-12-02 公益財団法人川崎市産業振興財団 非吸着性またはスーパーステルス小胞
JP2025535944A (ja) 2022-10-24 2025-10-30 エイジーエス・セラピューティクス・ソシエテ・パール・アクシオン・サンプリフィエ 微細藻類由来の細胞外小胞、鼻腔内投与時のそれらの生体内分布、及びそれらの使用
AU2023367741A1 (en) 2022-10-25 2025-05-01 Genentech, Inc. Therapeutic and diagnostic methods for multiple myeloma
WO2024173842A1 (en) 2023-02-17 2024-08-22 Erasca, Inc. Kras inhibitors
AU2024270495A1 (en) 2023-05-05 2025-10-09 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
TW202504641A (zh) 2023-06-08 2025-02-01 美商建南德克公司 用於淋巴瘤之診斷及治療方法的巨噬細胞特徵
WO2025024257A1 (en) 2023-07-21 2025-01-30 Genentech, Inc. Diagnostic and therapeutic methods for cancer
TW202515614A (zh) 2023-08-25 2025-04-16 美商建南德克公司 治療非小細胞肺癌之方法及組成物
WO2025176847A1 (en) 2024-02-21 2025-08-28 Ags Therapeutics Sas Ocular delivery of active agents via microalgae extracellular vesicles

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9004483D0 (en) * 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
AU7228896A (en) * 1995-10-16 1997-05-07 Fujisawa Pharmaceutical Co., Ltd. Heterocyclic compounds as h+-atpases
DE69633196D1 (de) * 1995-10-16 2004-09-23 Fujisawa Pharmaceutical Co Heterocyclische verbindungen als h+-atpasen

Also Published As

Publication number Publication date
UA73073C2 (uk) 2005-06-15
SK135799A3 (en) 2000-05-16
NO313827B1 (no) 2002-12-09
AU750906B2 (en) 2002-08-01
ATE250583T1 (de) 2003-10-15
TR199902946T2 (xx) 2000-03-21
HUP0002112A3 (en) 2000-10-30
EP0973746A1 (en) 2000-01-26
BR9808478A (pt) 2003-09-30
JP2009197019A (ja) 2009-09-03
HUP0002112A2 (hu) 2000-09-28
EP0973746B1 (en) 2003-09-24
HK1024917A1 (en) 2000-10-27
PT973746E (pt) 2004-02-27
ES2209124T3 (es) 2004-06-16
PL196471B1 (pl) 2008-01-31
DK0973746T3 (da) 2004-02-02
KR20010006047A (ko) 2001-01-15
CN1259125A (zh) 2000-07-05
IL132192A0 (en) 2001-03-19
JP5086301B2 (ja) 2012-11-28
DE69818442D1 (de) 2003-10-30
CN1121391C (zh) 2003-09-17
CZ299136B6 (cs) 2008-04-30
NO994798L (no) 1999-11-24
AU6877798A (en) 1998-10-22
CA2285241A1 (en) 1998-10-08
AR012313A1 (es) 2000-10-18
NO994798D0 (no) 1999-10-01
WO1998043960A1 (en) 1998-10-08
DE69818442T2 (de) 2004-07-08
NZ337782A (en) 2001-04-27
JP4537500B2 (ja) 2010-09-01
CA2285241C (en) 2013-06-25
SK284922B6 (sk) 2006-02-02
ZA982771B (en) 1999-10-01
TWI228492B (en) 2005-03-01
CZ351799A3 (cs) 2000-05-17
RU2202551C2 (ru) 2003-04-20
PL335999A1 (en) 2000-06-05
HU229549B1 (en) 2014-01-28
JP2001519788A (ja) 2001-10-23

Similar Documents

Publication Publication Date Title
KR100531969B1 (ko) 치환된 3-시아노 퀴놀린, 이를 함유하는 약제학적 조성물 및 이의 제조방법
US6002008A (en) Substituted 3-cyano quinolines
KR100817423B1 (ko) 시아노퀴놀린을 포함하는 결장 폴립의 치료 또는 억제를 위한 약제학적 조성물
US6384051B1 (en) Method of treating or inhibiting colonic polyps
US8148532B2 (en) Spiro substituted compounds as angiogenesis inhibitors
CA2223016C (en) Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of her-2 autophosphorylation properties
KR20090108086A (ko) 췌장암 치료용 조성물
KR20100090690A (ko) 혈관 신생 저해 물질과 항종양성 백금 착물의 병용
AU2001245452A1 (en) Use of cyanoquinolines for treating or inhibiting colonic polyps
JP2002525359A (ja) プロテインチロシンキナーゼインヒビターとしての置換３−シアノキノリン
HK1024917B (en) Substituted 3-cyano quinolines

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19991004

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20030402

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20050321

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20050329

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20050909

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20051123

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20051124

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20081007

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20091012

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20101029

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20111028

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20121030

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20121030

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20131030

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20131030

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20141030

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20141030

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20150930

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20150930

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20161028

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20161028

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20170929

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20170929

Start annual number: 13

End annual number: 13

EXPY Expiration of term
PC1801 Expiration of term

Termination date: 20181002

Termination category: Expiration of duration